Rozanolixizumab, An Anti-Fcrn Antibody: Final Results From A Phase Ii, Multiple-Dose Study In Patients With Primary Immune ThrombocytopeniaTadeusz Robak,Maciej Kaźmierczak,Isidro Jarque,Vasile Musteata,Jacek Trelinski,Nichola Cooper,Peter Kiessling,Ute Massow,Franz Woltering,Rose Snipes,Juan Ke,Grant Langdon,Birgit Haier,James B. Bussel,Stephen JollesBLOOD(2019)引用 6|浏览24暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要